GSE255685 provides per-sample processed expression-score files; values are not raw counts.
| Gene | Pathway | Expression (rlog) | vs Cohort | Cohort Median | %ile |
|---|---|---|---|---|---|
| APOE | Lipid Metabolism | 1.82 | bar=donor line=cohort median | 2.02 | 18.1% |
| FOXO3 | Insulin/IGF-1 Signaling | 9.88 | bar=donor line=cohort median | 9.99 | 34.6% |
| CETP | Lipid Metabolism | 4.82 | bar=donor line=cohort median | 5.05 | 21.3% |
| SIRT6 | Sirtuin Family | 8.33 | bar=donor line=cohort median | 8.34 | 47.1% |
| SIRT1 | Sirtuin Family | 9.00 | bar=donor line=cohort median | 8.72 | 94.1% |
| SIRT3 | Sirtuin Family | 7.33 | bar=donor line=cohort median | 7.49 | 22.0% |
| IGF1R | Insulin/IGF-1 Signaling | 9.96 | bar=donor line=cohort median | 10.21 | 28.1% |
| KLOTHO | Anti-aging | 2.36 | bar=donor line=cohort median | 2.51 | 27.8% |
| APOC3 | Lipid Metabolism | -2.11 | bar=donor line=cohort median | -2.11 | 6.3% |
| IL6 | Inflammation | 1.12 | bar=donor line=cohort median | 1.16 | 39.3% |
| TERT | Telomere Maintenance | 1.59 | bar=donor line=cohort median | 1.51 | 66.9% |
| IRS2 | Insulin/IGF-1 Signaling | 10.06 | bar=donor line=cohort median | 9.81 | 67.2% |
| TP53 | Tumor Suppression | 9.01 | bar=donor line=cohort median | 8.92 | 65.4% |
| SHC1 | Signal Transduction | 9.43 | bar=donor line=cohort median | 9.35 | 75.5% |
| ACE | Signal Transduction | 4.14 | bar=donor line=cohort median | 4.64 | 5.9% |
| # | Gene | ID | Type | Expression (Expression score) | Count |
|---|---|---|---|---|---|
| 1 | MT-RNR2 | 17.4 | 0 | ||
| 2 | B2M | 16.9 | 0 | ||
| 3 | EEF1A1 | 16.8 | 0 | ||
| 4 | ACTB | 16.5 | 0 | ||
| 5 | MT-CO1 | 16.5 | 0 | ||
| 6 | HLA-B | 15.8 | 0 | ||
| 7 | MT-RNR1 | 15.8 | 0 | ||
| 8 | HLA-E | 15.7 | 0 | ||
| 9 | MT-ND4 | 15.6 | 0 | ||
| 10 | MT-CO2 | 15.4 | 0 |
| # | Gene | Type | Expression | vs Cohort | Group Median | Cohort Median | %ile |
|---|---|---|---|---|---|---|---|
| 1 | S100A8 | 13.7 | bar=donor line=cohort median | 14.4 | 14.2 | 21.3% | |
| 2 | S100A9 | 15.2 | bar=donor line=cohort median | 15.8 | 15.5 | 26.0% | |
| 3 | IL1B | 9.2 | bar=donor line=cohort median | 8.8 | 9.3 | 42.5% | |
| 4 | CXCL8 | 11.8 | bar=donor line=cohort median | 12.2 | 11.4 | 61.1% |
| # | Gene | Type | Expression | vs Cohort | Group Median | Cohort Median | %ile |
|---|---|---|---|---|---|---|---|
| 5 | MPO | 6.7 | bar=donor line=cohort median | 6.1 | 6.1 | 80.1% | |
| 6 | FCGR3B | 14.4 | bar=donor line=cohort median | 14.7 | 14.7 | 23.8% |
| # | Gene | Type | Expression | vs Cohort | Group Median | Cohort Median | %ile |
|---|---|---|---|---|---|---|---|
| 7 | LYZ | 14.1 | bar=donor line=cohort median | 14.3 | 14.3 | 27.8% |
| # | Gene | Type | Expression | vs Cohort | Group Median | Cohort Median | %ile |
|---|---|---|---|---|---|---|---|
| 8 | CD3D | 10.4 | bar=donor line=cohort median | 10.6 | 10.4 | 55.7% | |
| 9 | CD3E | 12.0 | bar=donor line=cohort median | 12.1 | 12.0 | 61.1% |
| # | Gene | Type | Expression | vs Cohort | Group Median | Cohort Median | %ile |
|---|---|---|---|---|---|---|---|
| 10 | MS4A1 | 11.0 | bar=donor line=cohort median | 10.8 | 10.9 | 60.4% |
| # | Gene | Type | Expression | vs Cohort | Group Median | Cohort Median | %ile |
|---|---|---|---|---|---|---|---|
| 11 | NKG7 | 12.3 | bar=donor line=cohort median | 12.2 | 11.7 | 84.8% | |
| 12 | GNLY | 12.8 | bar=donor line=cohort median | 12.4 | 12.1 | 84.4% |
| # | Gene | Type | Expression | vs Cohort | Group Median | Cohort Median | %ile |
|---|---|---|---|---|---|---|---|
| 16 | MT-CO1 | 16.5 | bar=donor line=cohort median | 16.5 | 16.4 | 65.1% | |
| 17 | MT-CO2 | 15.4 | bar=donor line=cohort median | 15.6 | 15.3 | 65.1% | |
| 18 | MT-ND1 | 15.2 | bar=donor line=cohort median | 15.3 | 15.2 | 46.8% |